A retrospective multicenter study validating predictive biomarkers of Ipilimumab treatment in metastatic melanoma patients.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms CARAMEL
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
- 26 Jul 2016 New trial record
- 07 Jun 2016 Interim results (n=70) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology